Christopher Kennedy
Cardiovascular Disease · Bristol, TNNPI 1487682365
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 220 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Abbott at 34.5% of the total. Reporting peaked in 2019 at $767 and has fallen 54.9% since, to $346 in 2025.
Across 220 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Novartis$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$383
- Medtronic$329
- Boehringer Ingelheim$108
- AstraZeneca$82
- plus $504 from 13 others
What the payments were for
- Food & beverage$3,830100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 65 | $1,325 |
| Novartis | 71 | $1,111 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $383 |
| Medtronic(2 entities) | 13 | $329 |
| Boehringer Ingelheim | 7 | $108 |
| AstraZeneca | 7 | $82 |
| Johnson & Johnson | 6 | $81 |
| Cardiovascular Systems Inc. | 4 | $67 |
| Amgen | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Philips North America LLC | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Abiomed | 2 | $33 |
| Pfizer | 2 | $26 |
| Bayer | 1 | $19 |
| Merck | 1 | $14 |
| Boston Scientific | 1 | $14 |
How this compares
$3,843 in reported general payments places this provider in the 60th percentile of 429 cardiovascular disease providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $21,543 |
| Carvedilol | 21 | $187 |
| Metoprolol Succinate | 14 | $152 |
| ClopidogrelClopidogrel Bisulfate | 14 | $62 |
| Metoprolol Tartrate | 14 | $58 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $26 | $21,54326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Bristol
- Jonathan BurressBristol$43K
- Charles VillochBristol$26K
- David MetzgerKingsport$555K
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Steven GubinMemphis$248K
- Andrew ZurickNashville$231K
- Mark ZenkerNashville$225K
- Selcuk TombulChattanooga$198K
- George CrossleyNashville$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.